Author

B. Akosman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

C. G. Lee· 5 shared J. A. Elias· 5 shared S. Kamle· 5 shared C.-M. Lee· 4 shared B. Ma· 3 shared A. Fiser· 1 shared C. Guetta-Terrier· 1 shared C. H. He· 1 shared

Activity by Year

2021-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

C. G. Lee

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CHI3L1 Enhances Melanoma Lung Metastasis via Regulation of T cell Co-stimulators and CTLA-4/B7 Axis

B. Ma, S. Kamle, B. Akosman, H. Khan, C.-M. Lee, C. G. Lee, J. A. Elias

This study shows CHI3L1 promotes melanoma lung metastasis by inhibiting T cell co-stimulators and stimulating CTLA-4/B7 axis, with combined anti-CHI3L1 and anti-CTLA-4 antibodies showing synergistic antitumor effects.

bioRxiv · Jun 23, 2022Immunology

Chi3l1 is a modulator of glioma stem cell states and a therapeutic vulnerability for glioblastoma

C. Guetta-Terrier, D. Karambizi, B. Akosman, J.-S. Chen, S. Kamle, J. E. Fajardo, A. Fiser, R. Singh, S. A. Toms, C. G. Lee, J. A. Elias, N. Tapinos

This study shows Chi3l1 modulates glioma stem cell states by altering transcription factor activity and cell state transitions, and demonstrates anti-Chi3l1 antibody treatment inhibits glioblastoma growth.

bioRxiv · Oct 1, 2021 · PreprintCancer Biology

Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis

J.-H. Lee, C.-M. Lee, J. H. Lee, M.-O. Kim, J. W. Park, S. Kamle, B. Akosman, E. L. Herzog, X. Y. Peng, J. A. Elias, C. G. Lee

This study identifies Kasugamycin as a novel CHIT1 inhibitor with strong antifibrotic effects in pulmonary fibrosis models.

bioRxiv · Feb 25, 2021Immunology

Chitinase 3-like-1 Stimulates PD-L1 and Other Immune Checkpoint Inhibitors

B. Ma, B. Akosman, S. Kamle, C.-M. Lee, J. S. Koo, C. G. Lee, J. A. Elias

This study shows Chi3l1 promotes PD-L1 and other immune checkpoint inhibitors in melanoma, suggesting combined targeting of Chi3l1 and PD-1-PD-L1 as a therapeutic strategy for pulmonary metastasis.

bioRxiv · Jan 15, 2021 · PreprintCancer Biology

Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19

S. Kamle, B. Ma, C. H. He, B. Akosman, Y. Zhou, C.-M. Lee, W. S. El-Deiry, K. Huntington, O. Liang, J. T. Machan, M.-J. Kang, H. J. Shin, E. Mizoguchi, C. G. Lee, J. A. Elias

This study identifies CHI3L1 as a key mediator of aging-related severity in COVID-19 by stimulating ACE2 and SPP expression, and shows it is a therapeutic target.

bioRxiv · Jan 5, 2021Immunology